Microbix Biosystems Inc T.MBX

Alternate Symbol(s): MBXBF

Healthcare Biotechnology

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.

TSX:MBX - Post by User

Microbix Biosystems Inc > StatCan just dropped a bombshell...

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Dec 08, 2023 5:20pm

128 Views

Post# 35775717

RE:StatCan just dropped a bombshell...

Government policy flipped to 'don't test' for COVID...
Given the increased cumulative risk of long COVID with each infection they may be forced to reevaluate policy. Widespread repeat infection is going to be costly with each new wave.

prophetoffactz wrote:

@lisa_iannattone

StatCan just dropped a bombshell report on LC. This is the most important figure. It highlights that the risk of long term symptoms is cumulative, it increases with increasing number of infections. By 3+ infections, 38% report long term symptoms — that’s 1 in every 2.6 people.